: Regeneron, Sanofi’s Dupixent is one step closer to approval for young children in Europe


Shares of Regeneron Pharmaceuticals Inc. REGN, +0.07% gained about 2.5% in premarket trading on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi SAN, -0.19% SNY, -0.66%, for children as young as six months old. European regulators are expected to make a final decision in the coming months. Regeneron’s stock has gained 21.9% over the past year, while the broader S&P 500 SPX, +0.25% is down 6.6%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: More than 68,000 global tech-sector employees have lost jobs in 2023: layoff-data tracker
Next articleThe Big Move: My husband and I rent our second home to our son and his wife. Now we want him to own this house, but keep our 2.5% mortgage rate. How can we do that?


Please enter your comment!
Please enter your name here